LYRA LYRA THERAPEUTICS INC revenue, earnings and financials

For the quarter ended December 31, 2025, LYRA THERAPEUTICS INC reported revenue of $7.00K (down 96.7% from a year earlier), net income of −$6.95M and diluted EPS of −$9.60; over the last four quarters revenue was $398K and net income −$28.9M; for the fiscal year ended December 2025 revenue was $398K, down 74.1% on the year before.

LYRA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $398K, gross profit n/a, operating income −$31.0M, net income −$28.9M (margin -7266.1%), EPS −$18.62
• Fiscal year ended Dec 2024: revenue $1.53M, gross profit n/a, operating income −$96.3M, net income −$93.4M (margin -6090.9%), EPS −$71.75
• Fiscal year ended Dec 2023: revenue $1.56M, gross profit n/a, operating income −$67.1M, net income −$62.7M (margin -4023.1%), EPS −$1.26
• Fiscal year ended Dec 2022: revenue $1.36M, gross profit n/a, operating income −$56.3M, net income −$55.3M (margin -4055.6%), EPS −$1.83
• Fiscal year ended Dec 2021: revenue $285K, gross profit n/a, operating income −$43.6M, net income −$43.5M (margin -15267.7%), EPS −$3.35

LYRA quarterly revenue and earnings

• Quarter ended Dec 31, 2025 (from the annual report): revenue $7.00K (down 96.7% year over year), net income −$6.95M, EPS −$9.60
• Quarter ended Sep 30, 2025: revenue $25.0K (down 87.2% year over year), net income −$5.98M, EPS −$3.38
• Quarter ended Jun 30, 2025: revenue $183K (down 69.4% year over year), net income −$7.44M, EPS −$5.51
• Quarter ended Mar 31, 2025: revenue $183K (down 65.6% year over year), net income −$8.55M, EPS −$0.13
• Quarter ended Dec 31, 2024 (from the annual report): revenue $209K (up 43.2% year over year), net income −$11.0M, EPS −$25.57
• Quarter ended Sep 30, 2024: revenue $195K (down 64.2% year over year), net income −$11.9M, EPS −$9.07
• Quarter ended Jun 30, 2024: revenue $598K (up 30.6% year over year), net income −$48.1M, EPS −$36.76
• Quarter ended Mar 31, 2024: revenue $532K (up 29.8% year over year), net income −$22.5M, EPS −$0.35
• Quarter ended Dec 31, 2023 (from the annual report): revenue $146K (up 1227.3% year over year), net income −$15.2M, EPS −$0.19
• Quarter ended Sep 30, 2023: revenue $544K (up 51.5% year over year), net income −$15.7M, EPS −$0.27
• Quarter ended Jun 30, 2023: revenue $458K (down 12.8% year over year), net income −$15.6M, EPS −$0.36
• Quarter ended Mar 31, 2023: revenue $410K (down 12.4% year over year), net income −$16.3M, EPS −$0.44
• Quarter ended Dec 31, 2022 (from the annual report): revenue $11.0K, net income −$14.2M, EPS −$0.09
• Quarter ended Sep 30, 2022: revenue $359K (up 2464.3% year over year), net income −$14.8M, EPS −$0.40
• Quarter ended Jun 30, 2022: revenue $525K, net income −$14.4M, EPS −$0.42
• Quarter ended Mar 31, 2022: revenue $468K, net income −$11.9M, EPS −$0.92
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$13.6M, EPS −$1.05
• Quarter ended Sep 30, 2021: revenue $14.0K, net income −$11.1M, EPS −$0.85
• Quarter ended Jun 30, 2021: revenue n/a, net income −$11.0M, EPS −$0.85
• Quarter ended Mar 31, 2021: revenue n/a, net income −$7.80M, EPS −$0.60

LYRA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$28.9M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$70.0M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$63.3M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$43.4M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$25.8M, share buybacks n/a

LYRA balance sheet

• Dec 31, 2025: cash $15.9M, total assets $36.1M, total liabilities $46.8M, shareholders' equity −$10.7M
• Sep 30, 2025: cash $22.1M, total assets $43.7M, total liabilities $48.0M, shareholders' equity −$4.33M
• Jun 30, 2025: cash $29.8M, total assets $52.6M, total liabilities $51.0M, shareholders' equity $1.62M
• Mar 31, 2025: cash $31.7M, total assets $56.3M, total liabilities $52.4M, shareholders' equity $3.87M
• Dec 31, 2024: cash $40.6M, total assets $66.3M, total liabilities $54.8M, shareholders' equity $11.6M
• Sep 30, 2024: cash $23.8M, total assets $78.8M, total liabilities $58.1M, shareholders' equity $20.6M
• Jun 30, 2024: cash $31.9M, total assets $94.6M, total liabilities $63.6M, shareholders' equity $31.0M
• Mar 31, 2024: cash $15.8M, total assets $142M, total liabilities $64.0M, shareholders' equity $77.5M

What is LYRA's revenue?

LYRA THERAPEUTICS INC reported $398K of revenue over its last four quarters, through December 31, 2025.

Is LYRA profitable?

No. LYRA THERAPEUTICS INC lost $28.9M over the last four quarters.

What is LYRA's EPS?

Diluted earnings per share over the last four quarters were −$18.62; −$9.60 in the latest quarter.

LYRA ownership and insider trades · All stocks